Atlas FDA

Predicate Research Report · generated 2026-08-22 · Print / save as PDF · Save to account

Proxima Therapeutics, Inc. · Predicate Candidate Screening

5 FDA 510(k) clearances under this manufacturer; the 50 most recent screened below.

194 daysmedian FDA review time
340 days90th percentile
5clearances measured
K-numberDeviceApplicantDecidedReview daysRecalls (K-match)
K041929MAMMOSITE II RADIATION THERAPY SYSTEM (RTS) TRAY, MAMMOSITE Proxima Therapeutics, Inc.2004-08-26380
K032067MAMMOSITE RADIATION THERAPY SYSTEM (RTS) TRAY, MAMMOSITE HDRProxima Therapeutics, Inc.2004-02-102220
K030558MAMMOSITE RADIATION THERAPY SYSTEM (RTS) TRAY, MAMMOSITE HDRProxima Therapeutics, Inc.2003-05-21890
K011690MAMMOSITE RADIATION THERAPY SYSTEM (RTS) TRAY, MAMMOSITE HDRProxima Therapeutics, Inc.2002-05-063400
K003206GLIASITE RADIATION THERAPY SYSTEM (RTS), MODEL 1020,1030,104Proxima Therapeutics, Inc.2001-04-251940

Methodology

Recall counts reflect FDA recall records explicitly referencing each K-number; FDA links recalls to K-numbers inconsistently, so 0 means "none found in FDA records," not "never recalled." Data: FDA openFDA, refreshed weekly. Verify decisions of consequence against the primary source. Full candidate set and CSV export: atlasbyauro.com.

Prepared with Atlas

Predicate research, review-time statistics and recall monitoring for 510(k) teams: atlasbyauro.com/fda